Loading organizations...
§ Private Profile · Marlborough, MA, USA
Opsonic Therapeutics is a company.
Key people at Opsonic Therapeutics.
OxSonics Therapeutics develops the SonoTran® Platform, an ultrasound-based drug delivery system that enhances oncology drug efficacy within solid tumors. This innovative, drug-agnostic platform improves targeted delivery of therapeutics directly into cancerous tissues. By overcoming penetration challenges, OxSonics aims to increase local drug concentrations and improve treatment outcomes.
The company was co-founded by Dr. Colin Story, CEO, and Dr. Matthew Frohn, emerging as an Oxford University spin-out. OxSonics was established based on the insight that advanced ultrasound technology could significantly improve localized delivery of cancer therapeutics. Dr. Story, an expert in novel ultrasound devices, pioneered translating this research into a clinical solution.
OxSonics Therapeutics primarily serves the oncology market, benefiting patients by optimizing cancer treatments. Its vision is to maximize the therapeutic potential of anti-cancer drugs via SonoTran technology. The company endeavors to transform cancer care, enabling more potent and targeted drug action, leading to better outcomes for solid tumor malignancies.
Key people at Opsonic Therapeutics.
Opsonic Therapeutics is a life sciences company developing innovative therapeutics targeting infectious diseases and potentially oncology, with a focus on pathogen-extracting therapies for conditions like sepsis and blood-borne infections.[1][2][4][5] It leverages recombinant protein engineering to harness opsonins—proteins that enhance pathogen clearance—and related technologies for peptide identification and cancer elimination.[2][5][6] The company serves patients with hard-to-treat infections and cancers, addressing critical gaps in current treatments where traditional drugs struggle with pathogen removal or tumor penetration, positioning it for growth in the biotech sector amid rising antimicrobial resistance and oncology demands.[1][2][4]
Opsonic Therapeutics emerged from advancements in opsonin biology and peptide engineering, with early activity traced to around 2009 when it collaborated on projects like using Cosmix technology to develop RAS peptides for therapeutic use against targets, indicating a foundational focus on molecular binding for disease intervention.[6] The company likely evolved from or alongside related entities like Opsonix, launched specifically to pioneer pathogen-extracting therapies for sepsis and blood-borne diseases, building on recombinant protein platforms.[2][4] Key milestones include its positioning as an innovator in infectious disease treatments, with potential extensions into oncology therapeutics designed to eliminate cancers and prevent recurrence, reflecting founder expertise in immunology and biotech engineering though specific founders are not detailed in available records.[1][5]
Opsonic Therapeutics rides the wave of antimicrobial resistance (AMR) and sepsis innovation, where blood-borne infections kill millions annually, amplified by post-pandemic awareness of novel therapeutics.[2][4] Timing aligns with surging investments in biotech platforms that mimic or enhance immune responses like opsonization, countering limitations of existing antibiotics amid global AMR crises. Market forces favoring it include regulatory pushes for sepsis solutions and oncology adjuncts, as solid tumor penetration challenges persist (noted in parallel tech like enhanced drug delivery).[3] It influences the ecosystem by advancing protein engineering tools, potentially enabling partnerships with larger pharma for scalable infectious disease and cancer pipelines.[1][5][6]
Opsonic Therapeutics is poised for clinical advancement in sepsis therapies and oncology extensions, with next steps likely involving trial data releases, partnerships for Cosmix/RAS scaling, and funding to propel pathogen-extracting platforms.[2][5][6] Trends like AI-driven peptide design and immune-mimetic biotech will accelerate its trajectory, evolving its role from niche innovator to key player in precision medicine ecosystems. As AMR escalates, its opsonin-based differentiators could redefine sepsis treatment, tying back to its core mission of transforming untreatable infections into manageable conditions.[1][4]
